Gastrointestinal tolerance of low FODMAP oral nutrition supplements in healthy human subjects: a randomized controlled trial

Jennifer Erickson, Renee Korczak, Qi Wang, Joanne Slavin, Jennifer Erickson, Renee Korczak, Qi Wang, Joanne Slavin

Abstract

Background: There has been increasing interest in utilizing a diet low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) for the treatment of irritable bowel syndrome (IBS), a functional gastrointestinal disease. While studies have indicated that this diet can be effective at symptom reduction, it is a restrictive diet and patients may find it challenging to find low FODMAP products to meet their nutrient needs. The primary objective of this study was to assess the gastrointestinal (GI) tolerance of three low FODMAP oral nutrition supplements (ONS) in healthy adults.

Methods: A double-blind randomized controlled crossover study was conducted in 21 healthy adults (19-32 years). Fasted subjects consumed one of four treatments at each visit, with a one week wash out period between visits. Each participant received all treatments. Treatments included three low FODMAP ONS formulas (A, B, and C) as well as a positive control consisting of 5 g fructooligosaccharides (FOS) mixed in lactose-free milk. Breath hydrogen was measured at baseline, 1, 2, 3, and 4 h post treatment consumption. Subjective GI symptom questionnaires were completed at baseline, 0.5, 1, 1.5, 2, 3, 4, 12, 24 and 48 h following treatment consumption. Mean breath hydrogen concentrations and baseline corrected area under the curve for both breath hydrogen and GI symptoms were analyzed and compared between treatments. Significance was determined at P < 0.05.

Results: The positive control resulted in higher breath hydrogen response compared to all three of the low FODMAP ONS beverages at 3 and 4 h after consumption. There were no differences in GI symptom response between treatments.

Conclusions: All treatments were well tolerated in healthy participants. The low FODMAP formulas resulted in a lower breath hydrogen response compared to the positive control, and may be better tolerated in individuals with IBS. More research should be conducted to better understand the GI tolerance of low FODMAP ONS in individuals with IBS.

Trial registration: The protocol for this study was registered on ClinicalTrials.gov in January 2016 (Clinical Trials ID: NCT02667184 ).

Keywords: Breath hydrogen; FODMAP; Gastrointestinal tolerance; Oral nutrition supplement.

Figures

Fig. 1
Fig. 1
Breath hydrogen response following consumption of low FODMAP ONS beverages and positive control in healthy adults

References

    1. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:712–721.e4. doi: 10.1016/j.cgh.2012.02.029.
    1. Rome III: The Functional Gastrointestinal Disorders. Third Edit. Degnon Associates, Inc.; 2006.
    1. Ford AC, Talley NJ. Irritable bowel syndrome. BMJ. 2012;345 sep04_1:e5836. doi: 10.1136/bmj.e5836.
    1. Chey WD. Food: The Main Course to Wellness and Illness in Patients With Irritable Bowel Syndrome. Am J Gastroenterol. 2016;111:366–371. doi: 10.1038/ajg.2016.12.
    1. Gastrointestinal Expert Group Therapeutic Guidelines Limited . Therapeutic guidelines: Gastrointestinal. 2011.
    1. National Institute of Health and Care Excellence . Irritable bowel syndrome in adults: diagnosis and management. London: NICE; 2015.
    1. Gibson PR, Shepherd SJ. Evidence-based dietary management of functional gastrointestinal symptoms: The FODMAP approach. J Gastroenterol Hepatol. 2010;25:252–258. doi: 10.1111/j.1440-1746.2009.06149.x.
    1. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146:67–75.e5. doi: 10.1053/j.gastro.2013.09.046.
    1. Stein K. Severely Restricted Diets in the Absence of Medical Necessity: The Unintended Consequences. J Acad Nutr Diet. 2014;114:986–994. doi: 10.1016/j.jand.2014.03.008.
    1. Shepherd SJ, Halmos E, Glance S. The role of FODMAPs in irritable bowel syndrome. Curr Opin Clin Nutr Metab Care. 2014;17:605–609. doi: 10.1097/MCO.0000000000000116.
    1. Halmos EP, Bogatyrev A, Ly E, Liels KL, Muir JG, Gibson PR. Challenges of Quantifying FODMAPs in Enteral Nutrition Formulas: Evaluation of Artifacts and Solutions. JPEN J Parenter Enteral Nutr. 2016;14860711665876. doi:10.1177/0148607116658763.
    1. Yoon SR, Lee JH, Lee JH, Na GY, Lee K-H, Lee Y-B, et al. Low-FODMAP formula improves diarrhea and nutritional status in hospitalized patients receiving enteral nutrition: a randomized, multicenter, double-blind clinical trial. Nutr J. 2015;14:116. doi: 10.1186/s12937-015-0106-0.
    1. Halmos EP. Role of FODMAP content in enteral nutrition-associated diarrhea. J Gastroenterol Hepatol. 2013;28(Suppl 4):25–28. doi: 10.1111/jgh.12272.
    1. Klosterbuer A, Roughead ZF, Slavin J. Benefits of dietary fiber in clinical nutrition. Nutr Clin Pract. 2011;26:625–635. doi: 10.1177/0884533611416126.
    1. Kamarul Zaman M, Chin K-F, Rai V, Majid HA. Fiber and prebiotic supplementation in enteral nutrition: A systematic review and meta-analysis. World J Gastroenterol. 2015;21:5372–5381. doi: 10.3748/wjg.v21.i17.5372.
    1. Cherbut C, Michel C, Raison V, Kravtchenko T, Severine M. Acacia Gum is a Bifidogenic Dietary Fibre with High Digestive Tolerance in Healthy Humans. Microb Ecol Health Dis. 2003;15:43–50.
    1. Yoon S-J, Chu D-C, Juneja LR. Physiological Functions of Partially Hydrolyzed Guar Gum. J Clin Biochem Nutr. 2006;39:134–144. doi: 10.3164/jcbn.39.134.
    1. Parisi G, Bottona E, Carrara M, Cardin F, Faedo A, Goldin D, et al. Treatment Effects of Partially Hydrolyzed Guar Gum on Symptoms and Quality of Life of Patients with Irritable Bowel Syndrome. A Multicenter Randomized Open Trial. Dig Dis Sci. 2005;50:1107–1112. doi: 10.1007/s10620-005-2713-7.
    1. Ghoshal UC. How to interpret hydrogen breath tests. J Neurogastroenterol Motil. 2011;17:312–317. doi: 10.5056/jnm.2011.17.3.312.
    1. Ong DK, Mitchell SB, Barrett JS, Shepherd SJ, Irving PM, Biesiekierski JR, et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol. 2010;25:1366–1373. doi: 10.1111/j.1440-1746.2010.06370.x.
    1. Simrén M, Stotzer P-O. Use and abuse of hydrogen breath tests. Gut. 2006;55:297–303. doi: 10.1136/gut.2005.075127.
    1. Bonnema AL, Kolberg LW, Thomas W, Slavin JL. Gastrointestinal tolerance of chicory inulin products. J Am Diet Assoc. 2010;110:865–868. doi: 10.1016/j.jada.2010.03.025.
    1. Bovenschen HJ, Janssen MJR, van Oijen MGH, Laheij RJF, van Rossum LGM, Jansen JBMJ. Evaluation of a gastrointestinal symptoms questionnaire. Dig Dis Sci. 2006;51:1509–1515. doi: 10.1007/s10620-006-9120-6.
    1. Magge S, Lembo A. Low-FODMAP Diet for Treatment of Irritable Bowel Syndrome. Gastroenterol Hepatol (N Y) 2012;8:739–745.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere